格隆汇2月11日丨衢州东峰(601515.SH)公布，公司回购股份用途拟将回购的股份全部用于实施员工持股 计划或股权激励。回购股份金额不低于人民币5,000万元（含）且不超过人民币10,000万元（含）；回购 价不超过人民币6.48元/股。 ...

公司所属全资风力发电企业通宝宁武清洁能源有限公司2025年第四季度发电量4,086万千瓦时，上网电 量4,018万千瓦时，上网电价均价(含税)329.96元/千千瓦时。2025年度发电量6,768万千瓦时，上网电量 6,637万千瓦时，上网电价均价(含税)326.97元/千千瓦时。市场化交易电量占上网电量100%。 格隆汇2月11日丨通宝能源(600780.SH)公布，公司所属全资火力发电企业山西阳光发电有限责任公司 2025年第四季度发电量151,092万千瓦时，同比下降13.73%；上网电量136,332万千瓦时，同比下降 14.34%；上网电价均价(含税)395.52元/千千瓦时，同比增加13.09%。2025年度发电量564,648万千瓦 时，同比下降8.58%；上网电量509,251万千瓦时，同比下降9.22%；上网电价均价（含税）380.18元/千 千瓦时，同比增加6.94%。市场化交易电量占上网电量100%，与上年持平。 ...

国家质检中心的筹建是公司在新能源机动车检测领域的重要战略布局，有利于充分发挥公司在车辆检测 认证领域的技术积累和资源优势，进一步拓展检测服务范围、提升核心竞争力和行业影响力，为公司高 质量发展提供更强有力的支撑。 格隆汇2月11日丨中机认检(301508.SZ)公布，控股子公司中机寰宇（山东）车辆认证检测有限公司（简 称"中机车辆"）于近日收到国家市场监督管理总局批复，获准筹建"国家新能源机动车质量检验检测中 心（山东）"（简称"国家质检中心"），该中心旨在服务新能源机动车产业高质量发展。 ...

Core Viewpoint - Zhu Cheng Technology (301280.SZ) announced that it holds a 60% stake in Wenzhou Zhu Chuang, which will distribute a cash dividend of 3 million yuan based on the unaudited undistributed profits as of December 31, 2025 [1] Group 1 - The company has received the full amount of the cash dividend prior to this announcement [1] - Wenzhou Zhu Chuang is a subsidiary included in the company's consolidated financial statements [1] - The profit distribution will increase the company's net profit in the parent company financial statements for 2026, but will not affect the consolidated net profit for 2026 [1]

Core Viewpoint - The company, Shengnuo Biopharmaceutical (688117.SH), has participated in the national centralized procurement process for the first to eighth batches of drugs, marking a significant step in expanding its market presence and enhancing competitiveness in the peptide pharmaceutical market [1] Group 1: Procurement Participation - The company’s wholly-owned subsidiary, Chengdu Shengnuo Biopharmaceutical Co., Ltd., has engaged in the new round of centralized procurement organized by the state, which is the first nationwide unified continuation of centralized procurement for chemical drugs [1] - The company’s products, including Acetate Octreotide Injection (selected in the seventh batch), Acetate Atosiban Injection (selected in the eighth batch), and Somatostatin Injection (selected in the eighth batch), are among those proposed for selection in this new round of procurement [1] Group 2: Market Impact - The centralized procurement will prioritize the use of selected drugs by medical institutions, ensuring the completion of the agreed procurement volume [1] - The selection in this procurement round reflects the stability and reliability of the company’s drug quality, which is expected to further expand the sales scale of the selected products and increase market share [1] - The implementation of the procurement contract is anticipated to positively impact the company's operational development and strengthen its competitiveness in the peptide pharmaceutical market [1]

Core Viewpoint - The company, Dongfang Tower (002545.SZ), has won contracts totaling approximately 110 million yuan from the State Grid Corporation of China, which represents about 2.63% of its audited revenue for 2024 [1] Group 1 - The State Grid Corporation of China announced the results of its first procurement for transmission and transformation projects in 2026 [1] - Dongfang Tower's successful bids are part of the 66th batch of procurement for ultra-high voltage projects in 2025 [1]

格隆汇2月11日｜国博电子(688375.SH)公告称，2025年度营业总收入为23.86亿元，较上年同期下降 7.92%；归属于母公司所有者的净利润为5.08亿元，同比增长4.72%。 ...

影响经营业绩的主要因素：报告期内，受行业宏观因素影响，公司业绩阶段性承压。面对外部环境变 化，公司始终聚焦核心优势，夯实技术研发，推进精益化管理，提升运营质效。 格隆汇2月11日丨国博电子(688375.SH)公布2025年度业绩快报，报告期内，公司实现营业总收入23.86亿 元，较上年同期下降7.92%；实现归属于母公司所有者的净利润5.08亿元，较上年同期增长4.72%；实现 归属于母公司所有者的扣除非经常性损益的净利润4.93亿元，较上年同期增长3.50%；实现基本每股收 益0.85元，较上年同期增长4.94%。 ...

格隆汇2月11日丨必创科技(300667.SZ)公布，全资子公司无锡必创传感科技有限公司（简称"无锡必 创"）于近日收到江苏省科学技术厅、江苏省财政厅、国家税务总局江苏省税务局联合颁发的《高新技 术企业证书》，本次高新技术企业认定系原《高新技术企业证书》有效期满后所进行的重新认定。 ...

Core Viewpoint - The demand for semiconductor packaging and testing equipment is continuously growing, leading to significant sales increases for the company's testing sorting machines [1] Group 1: Company Performance - The company is expected to achieve a net profit attributable to shareholders of 160-210 million yuan in 2025, representing a year-on-year increase of 103.87%-167.58% [1] - The non-recurring net profit attributable to shareholders is projected to be 155-205 million yuan, with a year-on-year increase of 128.83%-202.64% [1] Group 2: Market Demand - The demand for testing sorting machines is driven by advancements in computing power, automotive applications, and advanced packaging [1] - The global System on Chip (SoC) testing machine market is expected to grow from 6.8-6.9 billion USD in 2025 to 8.5-9.5 billion USD in 2026 [1] - The storage testing machine market is projected to increase from 2-2.1 billion USD in 2025 to 2.2-2.7 billion USD in 2026 [1] Group 3: Product Synergy - The demand for sorting machines is expected to rise in tandem with testing machines, particularly in the finished product testing phase [1]